Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland i...
Published in: | Journal of Internal Medicine |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Other Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wiley
2018
|
Subjects: | |
Online Access: | http://hdl.handle.net/2336/620592 https://doi.org/10.1111/joim.12740 |
id |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/620592 |
---|---|
record_format |
openpolar |
institution |
Open Polar |
collection |
Hirsla - Landspítali University Hospital research archive |
op_collection_id |
ftlandspitaliuni |
language |
English |
topic |
Hepatitis Lifrarbólga Lyfjameðferð Lyfjagjöf END12 TMD12 VEI12 RES12 FJA12 Hepatitis C Antiviral Agents Disease Eradication |
spellingShingle |
Hepatitis Lifrarbólga Lyfjameðferð Lyfjagjöf END12 TMD12 VEI12 RES12 FJA12 Hepatitis C Antiviral Agents Disease Eradication Olafsson, S. Tyrfingsson, T. Runarsdottir, V. Bergmann, O. M. Hansdottir, I. Björnsson, E. S. Johannsson, B. Sigurdardottir, B. Fridriksdottir, R. H. Löve, A. Hellard, M. Löve, T. J. Gudnason, T. Heimisdottir, M. Gottfredsson, M. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
topic_facet |
Hepatitis Lifrarbólga Lyfjameðferð Lyfjagjöf END12 TMD12 VEI12 RES12 FJA12 Hepatitis C Antiviral Agents Disease Eradication |
description |
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct-acting antiviral agents to the entire patient population, the two key aims of the project were to (i) offer a cure to patients and thus reduce the long-term sequelae of chronic hepatitis C, and (ii) to reduce domestic incidence of HCV in the population by 80% prior to the WHO goal of HCV elimination by the year 2030. An important part of the programme is that vast majority of cases will be treated within 36 months from the launch of the project, during 2016-2018. Emphasis is placed on early case finding and treatment of patients at high risk for transmitting HCV, that is people who inject drugs (PWID), as well as patients with advanced liver disease. In addition to treatment scale-up, the project also entails intensification of harm reduction efforts, improved access to diagnostic tests, as well as educational campaigns to curtail spread, facilitate early detection and improve linkage to care. With these efforts, Iceland is anticipated to achieve the WHO hepatitis C elimination goals well before 2030. This article describes the background and organization of this project. Clinical trial number: NCT02647879. Merck Astellas Gilead Gilead Sciences AbbVie BMS |
author2 |
1 Landspitali Univ Hosp, Div Gastroenterol & Hepatol, Reykjavik, Iceland Show more 2 Univ Iceland, Fac Med, Sch Hlth Sci, IS-101 Reykjavik, Iceland Show more 3 Univ Iceland, SAA Natl Ctr Addict Med, Reykjavik, Iceland Show more 4 Univ Iceland, Fac Psychol, Sch Hlth Sci, Reykjavik, Iceland Show more 5 Landspitali Univ Hosp, Div Infect Dis, Reykjavik, Iceland Show more 6 Landspitali Univ Hosp, Div Virol, Reykjavik, Iceland Show more 7 Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia Show more 8 Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia Show more 9 Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia Show more 10 Landspitali Univ Hosp, Dept Sci, Reykjavik, Iceland Show more 11 Landspitali Univ Hosp, Directorate Hlth, Reykjavik, Iceland Show more 12 Landspitali Univ Hosp, Div Finance, Reykjavik, Iceland Division of Gastroenterology and Hepatology; Landspitali University Hospital; Reykjavik Iceland SAA - National Center of Addiction Medicine; Reykjavik Iceland Division of Infectious Diseases; Landspitali University Hospital; Reykjavik Iceland Faculty of Medicine; School of Health Sciences; University of Iceland; Reykjavik Iceland Centre for Population Health; Burnet Institute; Melbourne VIC Australia Chief Epidemiologist; Directorate of Health; Landspitali University Hospital; Reykjavik Iceland |
format |
Article in Journal/Newspaper |
author |
Olafsson, S. Tyrfingsson, T. Runarsdottir, V. Bergmann, O. M. Hansdottir, I. Björnsson, E. S. Johannsson, B. Sigurdardottir, B. Fridriksdottir, R. H. Löve, A. Hellard, M. Löve, T. J. Gudnason, T. Heimisdottir, M. Gottfredsson, M. |
author_facet |
Olafsson, S. Tyrfingsson, T. Runarsdottir, V. Bergmann, O. M. Hansdottir, I. Björnsson, E. S. Johannsson, B. Sigurdardottir, B. Fridriksdottir, R. H. Löve, A. Hellard, M. Löve, T. J. Gudnason, T. Heimisdottir, M. Gottfredsson, M. |
author_sort |
Olafsson, S. |
title |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_short |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_full |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_fullStr |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_full_unstemmed |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_sort |
treatment as prevention for hepatitis c (trap hep c) - a nationwide elimination programme in iceland using direct-acting antiviral agents |
publisher |
Wiley |
publishDate |
2018 |
url |
http://hdl.handle.net/2336/620592 https://doi.org/10.1111/joim.12740 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://doi.wiley.com/10.1111/joim.12740 Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents 2018, 283 (5):500 Journal of Internal Medicine 09546820 doi:10.1111/joim.12740 http://hdl.handle.net/2336/620592 Journal of Internal Medicine |
op_rights |
Archived with thanks to Journal of Internal Medicine Open Access - Opinn aðgangur |
op_doi |
https://doi.org/10.1111/joim.12740 |
container_title |
Journal of Internal Medicine |
container_volume |
283 |
container_issue |
5 |
container_start_page |
500 |
op_container_end_page |
507 |
_version_ |
1766037602380546048 |
spelling |
ftlandspitaliuni:oai:www.hirsla.lsh.is:2336/620592 2023-05-15T16:47:31+02:00 Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents Olafsson, S. Tyrfingsson, T. Runarsdottir, V. Bergmann, O. M. Hansdottir, I. Björnsson, E. S. Johannsson, B. Sigurdardottir, B. Fridriksdottir, R. H. Löve, A. Hellard, M. Löve, T. J. Gudnason, T. Heimisdottir, M. Gottfredsson, M. 1 Landspitali Univ Hosp, Div Gastroenterol & Hepatol, Reykjavik, Iceland Show more 2 Univ Iceland, Fac Med, Sch Hlth Sci, IS-101 Reykjavik, Iceland Show more 3 Univ Iceland, SAA Natl Ctr Addict Med, Reykjavik, Iceland Show more 4 Univ Iceland, Fac Psychol, Sch Hlth Sci, Reykjavik, Iceland Show more 5 Landspitali Univ Hosp, Div Infect Dis, Reykjavik, Iceland Show more 6 Landspitali Univ Hosp, Div Virol, Reykjavik, Iceland Show more 7 Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia Show more 8 Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic, Australia Show more 9 Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia Show more 10 Landspitali Univ Hosp, Dept Sci, Reykjavik, Iceland Show more 11 Landspitali Univ Hosp, Directorate Hlth, Reykjavik, Iceland Show more 12 Landspitali Univ Hosp, Div Finance, Reykjavik, Iceland Division of Gastroenterology and Hepatology; Landspitali University Hospital; Reykjavik Iceland SAA - National Center of Addiction Medicine; Reykjavik Iceland Division of Infectious Diseases; Landspitali University Hospital; Reykjavik Iceland Faculty of Medicine; School of Health Sciences; University of Iceland; Reykjavik Iceland Centre for Population Health; Burnet Institute; Melbourne VIC Australia Chief Epidemiologist; Directorate of Health; Landspitali University Hospital; Reykjavik Iceland 2018 http://hdl.handle.net/2336/620592 https://doi.org/10.1111/joim.12740 en eng Wiley http://doi.wiley.com/10.1111/joim.12740 Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents 2018, 283 (5):500 Journal of Internal Medicine 09546820 doi:10.1111/joim.12740 http://hdl.handle.net/2336/620592 Journal of Internal Medicine Archived with thanks to Journal of Internal Medicine Open Access - Opinn aðgangur Hepatitis Lifrarbólga Lyfjameðferð Lyfjagjöf END12 TMD12 VEI12 RES12 FJA12 Hepatitis C Antiviral Agents Disease Eradication Article 2018 ftlandspitaliuni https://doi.org/10.1111/joim.12740 2022-05-29T08:22:21Z To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct-acting antiviral agents to the entire patient population, the two key aims of the project were to (i) offer a cure to patients and thus reduce the long-term sequelae of chronic hepatitis C, and (ii) to reduce domestic incidence of HCV in the population by 80% prior to the WHO goal of HCV elimination by the year 2030. An important part of the programme is that vast majority of cases will be treated within 36 months from the launch of the project, during 2016-2018. Emphasis is placed on early case finding and treatment of patients at high risk for transmitting HCV, that is people who inject drugs (PWID), as well as patients with advanced liver disease. In addition to treatment scale-up, the project also entails intensification of harm reduction efforts, improved access to diagnostic tests, as well as educational campaigns to curtail spread, facilitate early detection and improve linkage to care. With these efforts, Iceland is anticipated to achieve the WHO hepatitis C elimination goals well before 2030. This article describes the background and organization of this project. Clinical trial number: NCT02647879. Merck Astellas Gilead Gilead Sciences AbbVie BMS Article in Journal/Newspaper Iceland Hirsla - Landspítali University Hospital research archive Journal of Internal Medicine 283 5 500 507 |